Brief Report: SWOG S1400B (), A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)

BACKGROUND: S1400B is a biomarker-driven Lung-MAP sub-study evaluating the phosphatidylinositide 3-kinase (PI3K) inhibitor taselisib (GDC-0032) in patients with PI3K pathway-activated squamous NSCLC (SqNSCLC). METHODS: Eligible patients had tumoral PIK3CA alterations by next generation sequencing an...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Thorac Oncol
Main Authors: Langer, Corey J., Redman, Mary W., Wade, James L., Aggarwal, Charu, Bradley, Jeffrey D., Crawford, Jeffrey, Stella, Philip J., Knapp, Mark H., Miao, Jieling, Minichiello, Katherine, Herbst, Roy S., Kelly, Karen, Gandara, David R., Papadimitrakopoulou, Vassiliki A.
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7017958/
https://ncbi.nlm.nih.gov/pubmed/31158500
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jtho.2019.05.029
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados